A notable example is the application of ASO therapy in a mouse model of SCN1A-associated Dravet syndrome, where blocking a non-productive splicing event increased SCN1A-mRNA and NaV1.1 protein levels, ultimately reducing seizure frequency. Here, SCN1A is linked to encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.